Vienna oncology research centre Research & development Vienna oncology centre opening Group photo Inauguration of Angelika ...
Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary ...
(Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on ...
Experts from the University of of Dundee's Centre for Targeted Protein Degradation (CeTPD), working with Boehringer Ingelheim ...
Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...
Boehringer Ingelheim announced today that the FIBRONEERTM-IPF trial met its primary endpoint, which was the absolute change ...
Boehringer is advancing the development of SZN-413 to prepare it for potential future clinical testingSZN-413 is a bi-specific antibody targeting ...
The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.
New research from the University of Dundee shows potential breakthrough for hard to treat cancers. Experts from the ...
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...
Boehringer Ingelheim’s Stop Rabies program expands to drive essential vaccination and neutering initiatives in Marinduque. The Stop Rabies program in the Philippines, spearheaded by Boehringer ...
Boehringer Ingelheim pivotal phase-III FIBRONEER-IPF study of nerandomilast meets primary endpoint: Ingelheim, Germany Tuesday, September 17, 2024, 13:00 Hrs [IST] Boehringer Inge ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback